NASDAQ:STIM

Neuronetics (STIM) Stock Forecast, Price & News

$1.28

-0.07 (-4.81%)

(As of 02:33 PM ET)

Compare

Today's Range: $1.26
▼
$1.36
50-Day Range: $1.29
▼
$2.02
52-Week Range: $1.25
▼
$6.95

Volume: 86,897 shs
Average Volume: 186,519 shs
Market Capitalization: $37.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.50

Neuronetics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 639.3% Upside
$9.50 Price Target
Short Interest: Healthy
1.49% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$32,409 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.13) to ($0.93) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

171st out of 969 stocks

Surgical & Medical Instruments Industry

26th out of 100 stocks

3.5

Analyst's Opinion

Consensus Rating
Neuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.50, Neuronetics has a forecasted upside of 639.3% from its current price of $1.29.
Amount of Analyst Coverage
Neuronetics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.49% of the outstanding shares of Neuronetics have been sold short.
Short Interest Ratio / Days to Cover
Neuronetics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Neuronetics has recently decreased by 6.11%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Neuronetics does not currently pay a dividend.
Dividend Growth
Neuronetics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for STIM.

2.0

News and Social Media Coverage

News Sentiment
Neuronetics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Neuronetics this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Neuronetics to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,409.00 in company stock.
Percentage Held by Insiders
Only 5.20% of the stock of Neuronetics is held by insiders.
Percentage Held by Institutions
62.23% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.93) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neuronetics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neuronetics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Neuronetics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

STIM Price History

30 days | 90 days | 365 days | Advanced Chart

STIM Stock News Headlines

September 21, 2023 | benzinga.com

Board Member of Neuronetics Purchased $51K In Stock

September 12, 2023 | finance.yahoo.com

In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression

October 2, 2023 | Stansberry Research (Ad)

U.S. "Shadow Banks" About to Blow up again?

Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.

September 6, 2023 | msn.com

Neuronetics: Large Losses May Be Repelling Investors

August 24, 2023 | 247wallst.com

Cannell Capital Now Owns 8.45% of Neuronetics

August 19, 2023 | finance.yahoo.com

Cannell Capital LLC Reduces Stake in Neuronetics Inc

August 14, 2023 | finance.yahoo.com

Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform

August 11, 2023 | finance.yahoo.com

Neuronetics (STIM) Upgraded to Buy: What Does It Mean for the Stock?

October 2, 2023 | Goldco (Ad)

Warren Buffett: Stark Warning On Inflation

According to a recent letter to Berkshire Hathaway shareholders, “Billionaire Investment Guru Warren Buffett issues stark inflation warning”. The new numbers have shown a comeback for inflation, surging to its highest levels in six months, and it’s now looking like there’s little chance our policy makers can put this cat back in the bag. That’s why it’s critical you heed Warren’s Buffett’s advice and “brace yourself”, before it’s too late. Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!

August 9, 2023 | markets.businessinsider.com

Neuronetics (STIM) Receives a Buy from JMP Securities

August 8, 2023 | finance.yahoo.com

Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results

July 25, 2023 | finance.yahoo.com

Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call

July 22, 2023 | ca.finance.yahoo.com

STIM - Neuronetics, Inc.

July 19, 2023 | finance.yahoo.com

Neuronetics Announces Expanded TMS Therapy Access Through Aetna® Health Plans

July 17, 2023 | finance.yahoo.com

NeuroStar Achieves Milestone Regulatory Clearance in South Korea

July 11, 2023 | finance.yahoo.com

NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player

July 5, 2023 | morningstar.com

Neuronetics Inc STIM Stock Quote

June 12, 2023 | finance.yahoo.com

Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy

June 8, 2023 | finance.yahoo.com

Neuronetics, Inc. (NASDAQ:STIM) Could Be Riskier Than It Looks

May 26, 2023 | finance.yahoo.com

Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan

May 24, 2023 | finance.yahoo.com

Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference

May 23, 2023 | technews.tmcnet.com

New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction

May 15, 2023 | finance.yahoo.com

Neuronetics Wins 2023 Bell Seal for Workplace Mental Health

May 12, 2023 | msn.com

JMP Securities Reiterates Neuronetics (STIM) Market Outperform Recommendation

May 10, 2023 | marketwatch.com

TMS (Transcranial Magnetic Stimulation) Coil Market Forecast 2023-2030

May 9, 2023 | finance.yahoo.com

Neuronetics Reports Record First Quarter 2023 Financial and Operating Results

May 8, 2023 | finance.yahoo.com

Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR

See More Headlines

Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Company Calendar

Last Earnings: 8/08/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:STIM
CUSIP: N/A
CIK: 1227636
Web: www.neurostar.com
Phone: (610) 640-4202
Fax: 610-640-4206
Employees: 209
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.50
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +603.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,160,000.00
Net Margins: -46.16%
Pretax Margin: -46.16%
Return on Equity: -58.58%
Return on Assets: -28.46%

Debt

Debt-to-Equity Ratio: 0.81
Current Ratio: 5.17
Quick Ratio: 4.58

Sales & Book Value

Annual Sales: $65.21 million
Price / Sales: 0.60
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.10 per share
Price / Book: 0.64

Miscellaneous

Outstanding Shares: 28,870,000
Free Float: 27,372,000
Market Cap: $38.97 million
Optionable: Not Optionable
Beta: 1.83

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Keith J. Sullivan (Age 65)
Pres, CEO & Director
Comp: $1.53M

Mr. Stephen J. Furlong M.S. (Age 59)
Exec. VP, CFO & Treasurer
Comp: $787.87k

Mr. W. Andrew Macan (Age 50)
Exec. VP, GC, Chief Compliance Officer & Corp. Sec.
Comp: $646.55k

Mr. Rusty Page
Sr. VP of Operations & Quality

Ms. Lisa Metzner-Rosas
Sr. VP & Chief Marketing Officer

Ms. Kara Thornton
Sr. VP of HR

Ms. Sara Grubbs
Sr. VP & Chief Revenue Officer

Mr. Rick Grubbs
Sr. VP of National Accounts

Mr. Todd Cushman
Sr. VP of Bus. Devel.

Mr. Cory S. Anderson
Sr. VP of R&D and Clinical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STIM Stock - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STIM shares.
View STIM analyst ratings or view top-rated stocks.
What is Neuronetics' stock price forecast for 2023?: 2 brokers have issued 1 year price objectives for Neuronetics' shares. Their STIM share price forecasts range from $7.00 to $12.00. On average, they expect the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 603.7% from the stock's current price.
View analysts price targets for STIM or view top-rated stocks among Wall Street analysts.
How have STIM shares performed in 2023?: Neuronetics' stock was trading at $6.87 at the beginning of the year. Since then, STIM stock has decreased by 80.3% and is now trading at $1.35.
View the best growth stocks for 2023 here.
When is Neuronetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our STIM earnings forecast.
How were Neuronetics' earnings last quarter?: Neuronetics, Inc. (NASDAQ:STIM) posted its earnings results on Tuesday, August, 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.17. The firm had revenue of $17.61 million for the quarter, compared to analyst estimates of $17.44 million. Neuronetics had a negative trailing twelve-month return on equity of 58.58% and a negative net margin of 46.16%.
What guidance has Neuronetics issued on next quarter's earnings?: Neuronetics issued an update on its third quarter 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $17.00 million-$18.00 million, compared to the consensus revenue estimate of $17.80 million.

What other stocks do shareholders of Neuronetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).
When did Neuronetics IPO?: (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.
What is Neuronetics' stock symbol?: Neuronetics trades on the NASDAQ under the ticker symbol "STIM."
How do I buy shares of Neuronetics?: Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Neuronetics' stock price today?: One share of STIM stock can currently be purchased for approximately $1.35.
How much money does Neuronetics make?: Neuronetics (NASDAQ:STIM) has a market capitalization of $38.97 million and generates $65.21 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.
How many employees does Neuronetics have?: The company employs 209 workers across the globe.
How can I contact Neuronetics?: Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206.

This page (NASDAQ:STIM) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial